CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 162 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $3,357,600 | -74.4% | 80,000 | -75.8% | 0.05% | -71.0% |
Q4 2023 | $13,119,528 | +52.3% | 330,800 | +5.7% | 0.18% | +32.3% |
Q3 2023 | $8,613,760 | +118.8% | 313,000 | +186.1% | 0.13% | +75.0% |
Q1 2023 | $3,936,212 | -56.3% | 109,400 | -45.8% | 0.08% | -45.7% |
Q4 2022 | $8,998,683 | +54.0% | 201,900 | -2.9% | 0.14% | +75.0% |
Q3 2022 | $5,842,000 | -81.5% | 207,844 | -82.3% | 0.08% | -81.6% |
Q2 2022 | $31,589,000 | +83.6% | 1,171,700 | +131.9% | 0.44% | +110.1% |
Q1 2022 | $17,207,000 | -16.1% | 505,200 | -4.8% | 0.21% | -9.6% |
Q4 2021 | $20,509,000 | +63.0% | 530,700 | +127.8% | 0.23% | +59.0% |
Q3 2021 | $12,579,000 | +230.5% | 233,000 | +104.7% | 0.14% | +188.0% |
Q2 2021 | $3,806,000 | +116.4% | 113,800 | +13.3% | 0.05% | +25.0% |
Q4 2020 | $1,759,000 | – | 100,400 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |